FOLH1 and metastatic prostate carcinoma: While the benefit of treatment has been mainly investigated in the setting of metastatic, castrate-resistant prostate cancers, PSMA-targeted radiopharmaceuticals may also be beneficial in a hormone-sensitive, metastatic prostate cancer setting, and with oligometastatic disease.